Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × FED × Lung Neoplasms × Clear all

Phase

Phase NA 14 Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

OTHER 127 INDUSTRY 102 NIH 12 NETWORK 6 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Small Cell Lung Carcinoma 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

VA Office of Research and Development

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡